NLARx Newsletter Header
NLARx News
June 4, 2009
In This Issue
NLARx News
Executive Branch
Outrage of the Week
Prices & Access
Patents & Generics
Conflicts of Interest
Advertising & Marketing
Pharma Watch
PBM Watch
Comparartive Effectiveness
Medicare
Medicaid
Safety & Clinical Trials
Quick Links
Join Our Mailing List
NLARx News
CVS Caremark Merger Is Attacked by Pharmacists and State Lawmakers More
Drug Companies Spent Over $30 Million on Advertising in West Virginia More
In the States
TEXAS: PBM, Datamining, and Discount Card Bills Sent to Governor More
MINNESOTA: False Claims Act Is Signed Into Law More
PENNSYLVANIA: Gov. Rendell Wants to Expand  Seniors' Drug Program More
FLORIDA: Prescription Database Law Awaits Gov's Signature More
ALABAMA: State Scores Victories Against Pharmaceutical Companies in New Settlements More
OHIO: Legislature Holds Hearing on Gift Disclosure Bill More
Outrage of the Week
AstraZeneca Told Sales Reps to Lie About Seroquel-Diabetes Link More
Prices and Access to Healthcare
In Bad Economy, US Counties Join Rx Discount Plan More
State Drug Assistance for Seniors At Risk for Cuts More
More Small Firms Drop Health Care Amid Recession More
Industry, Doctors, Hospitals, Insurers, & Labor Write Obama on Cost Control Measures More
Patents and Generics
FTC Testifies in Support of Bill Banning "Pay-for-Delay" Settlements Between Brand and Generic Drug Companies More
Merck Could Lose Patent on Key Drug Singulair More
Judge Blocks Generic Pulmicort More
Conflicts of Interest
APA Cuts Continuing Medical Education Ties With Drugmakers More
Sen. Grassley Points to Another Academic Doctor's Industry Pay More
UCLA Doctor Didn't Report Industry Payments More
Advertising and Marketing
Cerner Markets Patient Data to Drug Companies, Researchers More
AstraZeneca to Disclose Payments Made to Health Care Professionals More
Study Examines Impact of Physician Promos More
FDA Gives Advice on Divulging Risks to Drug and Device Companies More
FDA Ofers Risk Communication Guidance More
FDA Takes New Look at DTC Drug Ads More
The Real Agenda of GSK's New Blog and Why the Authors' Identities are Cloaked More
Pharma Watch
The Drug Industry's Talking Points on Health Reform More
Only the Bad Times Are Good for Pharma More
AstraZeneca Sued Over Asthma Drug Development Deal More
Lilly CEO: No Plans For Separate Follow-On Biologics Unit More
Five Positive Signs for Cash-Strapped Biotech Industry More
European Biotechs Rust On the Auction Block More
Drug Companies' Overseas Operations Cause Tax Headaches More
PBM Watch
Cigna Comments Prompt Speculation On Drug-Benefits Unit Plans More
Express Scripts Plans Stock Offering More
Comparative Effectiveness Research
Study: Comparative Effectiveness Could Save Money, Improve Quality More
HHS to Consider Cost in Setting Research Priorities More
Drug Industry Intensifies Lobbying on Comparative Effectiveness More
Medicare
States Consider Scaling Back Funding for Medicare Drug Benefit Amid Economic Crisis More
Cost Shifting May Make Arthritis Medications Too Expensive for Medicare Beneficiaries More
Medicare Part D Too Complicated for Seniors to Identify Lowest-Cost Plan More
Compendia Conflicts of Interest Influence Medicare Drug Coverage More
Medicaid
DOJ and Health and Human Services Announce Anti-Fraud Task Force More
Sanofi to Pay $95.5M to Settle Medicaid Pricing Dispute More
Pharmaceutical Companies Agree to Pay Ohio $8.44 Million Settlement More
Safety and Clinical Trials
FDA Moves To Greater Openness More
The New Pragmatism at FDA More
FDA Message on Drug Ads: Don't Bury Risk Information More
FDA Top Dogs: Product Approvals Shouldn't Be Litmus Test More
Bausch & Lomb Settles Product Liability 600 Lawsuits More
Phony Tamiflu Sites Spike in Wake of Swine Flu More
Some Antidepressants May Risk Breast Cancer Return More
Seroquel Safety Lawsuit Rejected by Judge More
China Defends Safety of Drug Exports More
NIH Program Launched to Remove Barriers To Treatments for Rare, Neglected Diseases More